Roche has announced that it will start a new large clinical trial (Phase III study) for Elevidys, a gene therapy for Duchenne muscular dystrophy. This study is an important step toward making the treatment available to more patients, especially in Europe and other countries where access is still limited. The goal is to collect additional data that regulators need to approve the therapy more widely.
Elevidys is designed to treat the underlying cause of Duchenne by helping the body produce a shortened version of dystrophin, a protein that muscles need to stay strong. It is given as a one-time intravenous (IV) treatment. So far, studies suggest that it can slow the progression of the disease in boys who are still walking (ambulatory), which could help maintain muscle function for longer.
The new study will include about 100 young boys with Duchenne who are still able to walk. Researchers will compare those who receive Elevidys to those who receive a placebo (a treatment with no active drug) over about 72 weeks. One key measure will be how quickly a child can stand up from the floor, which is an important indicator of disease progression. After the main part of the study, boys who received the placebo will have the chance to receive the gene therapy.
This trial builds on more than six years of research and real-world experience, with over 1,200 individuals already treated globally. Elevidys is currently approved in several countries, including the United States and Japan, but not yet broadly available everywhere. Roche hopes this new study will strengthen the evidence and help bring the treatment to more families around the world.
It is hoped that there will be at least one trial site for this study in Canada, improving access for Canadian families. For families living with Duchenne, this represents continued progress toward more treatment options and, ultimately, better outcomes.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: